Differentiation in the angiotensin II receptor 1 blocker class on Autonomic function

Current Hypertension Reports

Volumn 3, Issue 1, 2001, Pages

  Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLIC ACID DERIVATIVE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; EPROSARTAN; IMIDAZOLE DERIVATIVE; THIOPHENE DERIVATIVE;

ADRENERGIC SYSTEM; ANIMAL; AUTONOMIC NEUROPATHY; DRUG ANTAGONISM; DRUG EFFECT; HEART RATE; HUMAN; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ACRYLATES; ANIMALS; ANTIHYPERTENSIVE AGENTS; AUTONOMIC NERVOUS SYSTEM DISEASES; HEART RATE; HUMANS; IMIDAZOLES; RATS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; THIOPHENES;

EID: 0041953678     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-001-0067-x     Document Type: Article

References (34)

1. Rahn KH, Barenbrock M, Hausberg M: The sympathetic nervous system in the pathogenesis of hypertension. J Hypertens 1999, 17(suppl 3): S11-S14.
2. Esler M, Jennings G, Korner P, et al.: Total, and organ-specific, noradrenaline plasma kinetics in essential hypertension. Clin Exp Hypertens [A] 1984, 6: 507-521.
3. Floras JS, Hara K: Sympathoneural and haemodynamic characteristics of young subjects with mild essential hypertension. J Hypertens 1993, 1 1: 647-655.
4. Julius S: The evidence for a pathophysiologic significance of the sympathetic overactivity in hypertension. Clin Exp Hypertens 1996, 18: 305-321.
5. Guzzetti S, Dassi S, Pecis M, et al.: Altered pattern of circadian neural control of heart period in mild hypertension. J Hypertens 1991, 9: 831-838.
6. Floras JS: Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol 1993, 22(suppl A):72A-84A.
7. Grassi G, Esler M: How to assess sympathetic activity in humans. J Hypertens 1999, 17: 719-734.
8. Krum H: Sympathetic activation and the role of beta-blockers in chronic heart failure. Aust N Z J Med 1999, 29: 418-427.
9. Colucci WS: Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 1997, 80: 15L-25L.
10. Cohn JN, Levine TB, Olivari MT, et al.: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 3 11: 819-823.
11. Mancia G, Grassi G, Giannattasio C, Seravalle G: Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999, 34: 724-728.
12. Palatini P: Elevated heart rate as a predictor of increased cardiovascular morbidity. J Hypertens 1999, 17(suppl 3): S3-S10.
13. Head GA: Role of AT1 receptors in the central control of sympathetic vasomotor function. Clin Exp Pharmacol Physiol Suppl 1996, 3: S93-S98.
14. Hirooka Y, Potts PD, Dampney RA: Role of angiotensin II receptor subtypes in mediating the sympathoexcitatory effects of exogenous and endogenous angiotensin peptides in the rostral ventrolateral medulla of the rabbit. Brain Res 1997, 772: 107-114.
15. Murakami H, Liu JL, Zucker IH: Blockade of AT1 receptors enhances baroreflex control of heart rate in conscious rabbits with heart failure. Am J Physiol 1996, 271: R303-R309.
16. Brooks DP, Ruffolo RR Jr: Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure. J Hypertens Suppl 1999, 17: S27-S32.
17. Cox SL, Ben A, Story DF, Ziogas J: Evidence for the involvement of different receptor subtypes in the pre- and postjunctional actions of angiotensin II at rat sympathetic neuroeffector sites. Br J Pharmacol 1995, 114: 1057-1063.
18. Guimaraes S, Paiva MQ, Moura D: Different receptors for angiotensin II at pre- and postjunctional level of the canine mesenteric and pulmonary arteries. Br J Pharmacol 1998, 124: 1207-1212.
19. Krum H, Goldsmith RL: Effects of pharmacological therapy on autonomic function in patients with chronic heart failure. Editorials Cardiol 1995, 1: 167-176.
20. McKelvie RS, Yusuf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999, 100: 1056-1064.
21. Middlekauff HR: Mechanisms and implications of autonomic nervous system dysfunction in heart failure. Curr Opin Cardiol 1997, 12: 265-275.
22. Grassi G, Turri C, Dell'Oro R, et al.: Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension. J Hypertens 1998, 16(12 Pt 1):1789-1796.
23. Worck RH, Ibsen H, Frandsen E, Dige-Petersen H: AT1 receptor blockade and the sympathoadrenal response to insulininduced hypoglycemia in humans. Am J Physiol 1997, 272(3 Pt 1): E415-E421.
24. Noll G, Wenzel RR, De Marchi S, et al.: Differential effects of captopril and nitrates on muscle sympathetic nerve activity in volunteers. Circulation 1997, 95: 2286-2292.
25. Clemson B, Gaul L, Gubin SS, et al.: Prejunctional angiotensin II receptors. Facilitation of norepinephrine release in the human forearm. J Clin Invest 1994, 93: 684-691.
26. Lyons D, Roy S, Kinirons M, Swift CG: Selective AT1 receptor antagonism enhances sympathetically mediated vasoconstriction in the human forearm [abstract 6A.5]. Presented at the First International Symposium on Angiotensin II Antagonists, October 1997, London.
27. Lyons D, Roy S, O'Byrne S, Swift CG: ACE inhibition: postsynaptic adrenergic sympatholytic action in men. Circulation 1997, 96: 911-915.
28. Ohlstein EH, Brooks D P, Feuerstein GZ, Ruffolo RR Jr: Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997, 55: 244-251.
29. Balt JC, Mathy MJ, Pfaffendorf M, Van Zwieten PA: Inhibition of angiotensin-induced facilitation of sympathetic neurotransmission in the pithed rat: a comparison between losartan, irbesartan, telmisartan and captopril. J Hypertens 2001, 19: 465-473.
30. Balt JC, Mathy MJ, Pfaffendorf M, Van Zwieten PA: Blockade of both pre- and post-synaptically located AT1 receptors by valsartan, candesartan, eprosartan and embusartan. Naunyn Schmiedeberg's Arch Pharmacol 2001;363(suppl):R75.
31. Brooks DP, Ohlstein EH, Ruffolo RR Jr: Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data. Am Heart J 1999, 138(3 Pt 2):246-251.
32. Edwards RM, Aiyar N, Ohlstein EH, et al.: Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992, 260: 175-181.
33. Brooks DP, Ruffolo RR Jr: Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure. J Hypertens Suppl 1999, 17: S27-S32.
34. Sega R: Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group. Blood Press 1999, 8: 114-121.